Heparin Léčiva

Heparin Léčiva is a pharmaceutical product that contains heparin sodium as its active ingredient. It is marketed in the European Union and is provided in an unspecified strength and dosage form, intended for intravenous or subcutaneous administration. As a prescription‑only anticoagulant, it is used under medical supervision to help manage clot‑related conditions.

Heparin Léčiva is employed in clinical practice to address several thrombotic conditions. It is indicated for patients who require anticoagulation therapy in various settings.

- Prevention and treatment of venous thromboembolism (VTE) - Prophylaxis of deep‑vein thrombosis (DVT) after surgery or immobilization - Prevention of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass - Management of acute coronary syndromes where rapid anticoagulation is needed - Use during cardiac catheterisation procedures to reduce procedural thrombosis risk

Heparin Léčiva may be associated with a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common: - Minor bleeding at injection sites - Bruising or hematoma formation - Nausea or mild gastrointestinal discomfort - Transient elevation of liver enzymes - Mild thrombocytopenia (platelet count decrease) - Localised redness or irritation

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding - Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation - Severe allergic reactions such as anaphylaxis - Spontaneous spinal or epidural hematoma - Acute renal impairment in rare cases

Before initiating Heparin Léčiva, clinicians should evaluate patient‑specific factors and monitor for potential complications. Key precautions include:

- Assess baseline coagulation parameters (aPTT, platelet count) and repeat monitoring during therapy - Use cautiously in patients with a history of bleeding disorders or recent major surgery - Avoid in individuals with known hypersensitivity to heparin or pork products - Consider dose adjustment in renal or hepatic impairment - Counsel pregnant or lactating patients only under specialist guidance - Ensure appropriate reversal agents (protamine sulfate) are available for emergency bleeding control

Heparin Léčiva can interact with several medications, influencing its anticoagulant effect or increasing bleeding risk.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without specialist oversight - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that potentiate bleeding - Thrombolytic agents such as alteplase or streptokinase

Use with caution: - Antiplatelet agents (clopidogrel, ticagrelor) where combined effect may be additive - Selective serotonin reuptake inhibitors (SSRIs) that can impair platelet function - Glycoprotein IIb/IIIa inhibitors used in interventional cardiology - Certain antibiotics (e.g., vancomycin) that may alter platelet counts